Table 1. Effects of the suppression of the expression of PSD-95/SAP90 in the spinal cord on the *N*-methyl-D-aspartate-induced thermal hyperalgesia

	Control	NMDA	MK-801 + NMDA	DNQX + NMDA	AS (25 μg) + NMDA	AS (50 μg) + NMDA	SE (50 μg) + NMDA	MS (50 μg) + NMDA
ΔTF latency (%)	− 1.23 ± 1.48	− 25.84 ± 1.91*	0.9 ± 3.0***	− 22.6 ± 3.13*	− 11.65 ± 2.46**.****	− 4.72 ± 2.49***	− 21.48 ± 1.55*	− 20.96 ± 1.68*

Percentage change of TF latency was calculated as described in the Experimental Procedures. AS: antisense; SE: sence; MS: missense. Data are presented as mean ± S.E.M. of six to 12 animals in each group.
*$P < 0.01$ significantly different from control.
**$P < 0.05$ significantly different from control.
***$P < 0.01$ significantly different from NMDA alone.
****$P < 0.05$ significantly different from NMDA alone.

Table 2. Effects of Antisense (AS), Sense (SE), and Missense (SE) Oligodeoxyribonucleotides and Saline on Isoflurane MAC, Blood Pressure (BP), and Heart Rate

	Saline (n = 14)	12.5 μg AS (n = 6)	25 μg AS (n = 6)	50 μg AS (n = 6)	50 μg SE (n = 6)	50 μg MS (n = 6)
MAC	1.16 ± 0.08	1.15 ± 0.18	0.98 ± 0.14*	0.72 ± 0.05*	1.15 ± 0.21	1.13 ± 0.15
BP (mmHg)						
Systolic	119.86 ± 10.58	127.58 ± 11.72	122.75 ± 10.81	129.58 ± 11.73	126.67 ± 10.40	121.33 ± 15.84
Diastolic	106.36 ± 7.78	112.58 ± 7.14	105.83 ± 7.89	112.50 ± 11.20	105.58 ± 13.07	105.75 ± 11.40
Heart rate (beats/min)	513.00 ± 40.78	534.80 ± 29.13	541.20 ± 16.70	514.20 ± 62.20	529.60 ± 22.61	524.70 ± 44.90

* $P < 0.01$ *versus* saline-treated (control) group.

MAC = minimum alveolar concentration.

Table 3. Mean (SD) Changes in Locomotor Test

Agents	Placing	Grasping	Righting
Saline	5 (0)	5 (0)	5 (0)
12.5 μg AS	5 (0)	5 (0)	5 (0)
25 μg AS	5 (0)	5 (0)	5 (0)
50 μg AS	4.83 (0.41)	4.67 (0.52)	4.83 (0.41)
50 μg SE	5 (0)	5 (0)	5 (0)
50 μg MS	5 (0)	5 (0)	5 (0)
Saline + 1.25 μg NMDA	5 (0)	5 (0)	5 (0)
50 μg AS + 1.25 μg NMDA	4.83 (0.41)	4.83 (0.41)	4.83 (0.41)

N = 6, five trials.

AS = antisense; SE = sense, MS = missense; NMDA = *N*-methyl-D-aspartate.